



Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions.

Programs listed here are manufacturer-approved treatment centers for which ETS has contracted rates in place or has access to rates through single case agreements for Skysona (elivaldogene autotemcel) which is approved to treat cerebral adrenoleukodystrophy.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at medicalservices@emergingtherapies.com.

▼ Denotes facilities at which ETS has gene therapy rates in place.

State	City	Program Listing
California	Palo Alto	Lucile Packard Children's Hospital ▼
Massachusetts	Boston	Boston Children's Hospital
Minnesota	Minneapolis	M Health Fairview University of Minnesota Masonic Children's Hospital ▼
Pennsylvania	Philadelphia	Children's Hospital Philadelphia ▼
Texas	Dallas	Children's Medical Center of Dallas